Post by icemandios on Jan 29, 2016 1:09:54 GMT
Just here for the opportunity to see what the market does about this: (And rj might have an interest)
SUNNYVALE, Calif., Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015.
Fiscal Second Quarter Highlights
Gross orders were $67.1 million; single and dual vault sites comprised more than 50 percent of total TomoTherapy® System orders; replacement orders to existing accounts comprised approximately 15 percent of all system orders
Total revenue was $108.9 million, an increase of 11 percent year-over-year or 15 percent on a constant currency basis
Gross profit margins expanded sequentially to 39.1 percent from 37.8 percent
Operating income was near breakeven compared to a loss of $3.6 million in the prior year
Adjusted EBITDA was $6.8 million compared to $3.7 million in the prior year
Cash, cash equivalents and investments increased $2.7 million compared to a decrease of $1.9 million in the prior year
"In the second quarter we achieved an all time high revenue quarter and near breakeven operating income, demonstrating that we are continuing to execute on each of our strategic commercial initiatives. Based on our commercial momentum, we expect that order and revenue growth in the second half of the fiscal year will be at levels well above overall market growth," said Joshua H. Levine, president and chief executive officer of Accuray. "Additionally, in January 2016 we took steps to improve our capital structure by closing on a $70 million senior secured loan and subsequently retiring $63.4 million of convertible notes which were to mature in August 2016. We believe this demonstrates confidence on the part of the financial community in our ability to execute our commercial strategies and drive positive EBITDA. With the retirement of the notes and our intent to pay the remaining convertible notes in cash we have reduced potential dilution by 10.6 million shares of our common stock."
Financial Highlights
Gross product orders totaled $67.1 million for the second fiscal quarter. Ending product backlog was $366.7 million.
Total revenue was $108.9 million, an increase of 11 percent from the prior fiscal year second quarter and an increase of 15 percent on a constant currency basis. The Americas region total revenue was $51.0 million and total revenue outside of the Americas region was $57.9 million. Product revenue increased 17 percent to $55.8 million while service revenue increased 5 percent to $53.1 million.
Total gross profit was $42.6 million or 39 percent of sales, comprised of product gross margin of 41 percent and service gross margin of 37 percent. This compares to total gross margin of 39 percent, product gross margin of 43 percent and service gross margin of 36 percent for the prior fiscal year second quarter. On a constant currency basis, total gross margin for the second quarter of fiscal 2016 was 41 percent.
Operating expenses were $42.7 million, an increase of 1 percent compared with $42.1 million in the prior fiscal second quarter. The increase was primarily due to higher legal expenses, related to the amended award of $2.1 million for damages to the Company's former China distributor as well as increased research and development expenses to support ongoing product development efforts. These increases were partially offset by reduced compensation related expenses in sales and marketing and general and administrative functions.
In November 2015 Accuray's former distributor in China was awarded an interim award for damages of approximately $3.4 million. In January 2016, the International Chamber of Commerce International Court of Arbitration revised the award based on a clerical error they believe occurred in their calculation of the maximum amount of damages. Accuray incurred an additional $2.1 million in expenses related to this amended award in the second quarter of fiscal 2016. The remaining issue to be finalized in the arbitration relates to the payment of attorneys' fees.
Net loss improved to $6.0 million, or $0.08 per share, for the second quarter of fiscal 2016, compared to a net loss of $10.0 million, or $0.13 per share, for the second quarter of fiscal 2015.
Adjusted EBITDA for the second quarter of fiscal 2016 was $6.8 million, compared to $3.7 million in the second quarter of the prior fiscal year.
Cash, cash equivalents and investments were $155.8 million as of December 31, 2015, an increase of $2.7 million from September 30, 2015.
Six Month Highlights
For the six months ended December 31, 2015, total revenue reached $198.5 million, representing an increase of 10 percent or 14 percent on a constant currency basis, from the comparable period of fiscal year 2015. Product revenue for the six month period was $95.8 million, representing an increase of 19 percent while service revenue was $102.8 million, representing 3% growth over the comparable prior fiscal year period.
Gross profit margin for the six months ended December 31, 2015 was 39 percent, comprised of product gross margin of 42 percent and service gross margin of 35 percent. This compares to total gross margin of 37 percent for the comparable prior fiscal year period.
Operating expenses were $83.8 million for the six months ended December 31, 2015, compared with $85.2 million in the comparable prior fiscal year period.
Net loss for the six months ended December 31, 2015 was $19.1 million, or $0.24 per share, compared to a net loss of $31.6 million, or $0.41 per share, for the comparable prior fiscal year period.
Adjusted EBITDA for the six months ended December 31, 2015 was a positive $5.7 million, compared to a loss of $4.8 million in the comparable prior fiscal year period.
Cash, cash equivalents, and investments increased $11.9 million from June 30, 2015.
2016 Financial Guidance
Accuray reaffirmed previously provided financial guidance for fiscal 2016. Total revenue is expected to be between $395 million to $410 million and adjusted EBITDA is expected to range between $25 million to $35 million. Accuray continues to expect that gross orders for the fiscal year will be approximately $295 million, which would represent a 10 percent increase year over year.
This financial guidance is unchanged from that provided on January 11, 2016.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss these results. Conference call dial-in information is as follows:
U.S. callers: (855) 867-4103
International callers: (262) 912-4764
Conference ID Number (U.S. and international): 19257397
Accuray Generates $108.9 Million in Second Quarter Revenues
Record Revenues Achieved as Commercial Execution Continues; Management Reaffirms Fiscal 2016 Guidance
SUNNYVALE, Calif., Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015.
Fiscal Second Quarter Highlights
Gross orders were $67.1 million; single and dual vault sites comprised more than 50 percent of total TomoTherapy® System orders; replacement orders to existing accounts comprised approximately 15 percent of all system orders
Total revenue was $108.9 million, an increase of 11 percent year-over-year or 15 percent on a constant currency basis
Gross profit margins expanded sequentially to 39.1 percent from 37.8 percent
Operating income was near breakeven compared to a loss of $3.6 million in the prior year
Adjusted EBITDA was $6.8 million compared to $3.7 million in the prior year
Cash, cash equivalents and investments increased $2.7 million compared to a decrease of $1.9 million in the prior year
"In the second quarter we achieved an all time high revenue quarter and near breakeven operating income, demonstrating that we are continuing to execute on each of our strategic commercial initiatives. Based on our commercial momentum, we expect that order and revenue growth in the second half of the fiscal year will be at levels well above overall market growth," said Joshua H. Levine, president and chief executive officer of Accuray. "Additionally, in January 2016 we took steps to improve our capital structure by closing on a $70 million senior secured loan and subsequently retiring $63.4 million of convertible notes which were to mature in August 2016. We believe this demonstrates confidence on the part of the financial community in our ability to execute our commercial strategies and drive positive EBITDA. With the retirement of the notes and our intent to pay the remaining convertible notes in cash we have reduced potential dilution by 10.6 million shares of our common stock."
Financial Highlights
Gross product orders totaled $67.1 million for the second fiscal quarter. Ending product backlog was $366.7 million.
Total revenue was $108.9 million, an increase of 11 percent from the prior fiscal year second quarter and an increase of 15 percent on a constant currency basis. The Americas region total revenue was $51.0 million and total revenue outside of the Americas region was $57.9 million. Product revenue increased 17 percent to $55.8 million while service revenue increased 5 percent to $53.1 million.
Total gross profit was $42.6 million or 39 percent of sales, comprised of product gross margin of 41 percent and service gross margin of 37 percent. This compares to total gross margin of 39 percent, product gross margin of 43 percent and service gross margin of 36 percent for the prior fiscal year second quarter. On a constant currency basis, total gross margin for the second quarter of fiscal 2016 was 41 percent.
Operating expenses were $42.7 million, an increase of 1 percent compared with $42.1 million in the prior fiscal second quarter. The increase was primarily due to higher legal expenses, related to the amended award of $2.1 million for damages to the Company's former China distributor as well as increased research and development expenses to support ongoing product development efforts. These increases were partially offset by reduced compensation related expenses in sales and marketing and general and administrative functions.
In November 2015 Accuray's former distributor in China was awarded an interim award for damages of approximately $3.4 million. In January 2016, the International Chamber of Commerce International Court of Arbitration revised the award based on a clerical error they believe occurred in their calculation of the maximum amount of damages. Accuray incurred an additional $2.1 million in expenses related to this amended award in the second quarter of fiscal 2016. The remaining issue to be finalized in the arbitration relates to the payment of attorneys' fees.
Net loss improved to $6.0 million, or $0.08 per share, for the second quarter of fiscal 2016, compared to a net loss of $10.0 million, or $0.13 per share, for the second quarter of fiscal 2015.
Adjusted EBITDA for the second quarter of fiscal 2016 was $6.8 million, compared to $3.7 million in the second quarter of the prior fiscal year.
Cash, cash equivalents and investments were $155.8 million as of December 31, 2015, an increase of $2.7 million from September 30, 2015.
Six Month Highlights
For the six months ended December 31, 2015, total revenue reached $198.5 million, representing an increase of 10 percent or 14 percent on a constant currency basis, from the comparable period of fiscal year 2015. Product revenue for the six month period was $95.8 million, representing an increase of 19 percent while service revenue was $102.8 million, representing 3% growth over the comparable prior fiscal year period.
Gross profit margin for the six months ended December 31, 2015 was 39 percent, comprised of product gross margin of 42 percent and service gross margin of 35 percent. This compares to total gross margin of 37 percent for the comparable prior fiscal year period.
Operating expenses were $83.8 million for the six months ended December 31, 2015, compared with $85.2 million in the comparable prior fiscal year period.
Net loss for the six months ended December 31, 2015 was $19.1 million, or $0.24 per share, compared to a net loss of $31.6 million, or $0.41 per share, for the comparable prior fiscal year period.
Adjusted EBITDA for the six months ended December 31, 2015 was a positive $5.7 million, compared to a loss of $4.8 million in the comparable prior fiscal year period.
Cash, cash equivalents, and investments increased $11.9 million from June 30, 2015.
2016 Financial Guidance
Accuray reaffirmed previously provided financial guidance for fiscal 2016. Total revenue is expected to be between $395 million to $410 million and adjusted EBITDA is expected to range between $25 million to $35 million. Accuray continues to expect that gross orders for the fiscal year will be approximately $295 million, which would represent a 10 percent increase year over year.
This financial guidance is unchanged from that provided on January 11, 2016.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss these results. Conference call dial-in information is as follows:
U.S. callers: (855) 867-4103
International callers: (262) 912-4764
Conference ID Number (U.S. and international): 19257397
Individuals interested in listening to the live conference call via the Internet may do so by logging on to Accuray's website, In addition, a dial-up replay of the conference call will be available beginning January 28, 2016 at 5:00 p.m. PT/8:00 p.m. ET and ending February 4, 2016. The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International), Conference ID: 19257397.
Use of Non-GAAP Financial Measures
Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedule below.
Accuray presents certain measures, such as period-over-period revenue growth, on a constant currency basis, which excludes the effects of foreign currency translation. Due to the continuing strengthening of the U.S. dollar against foreign currencies and the overall variability of foreign exchange rates from period to period, management uses these measures on a constant currency basis to evaluate period-over-period operating performance. Measures presented on a constant currency basis are calculated by translating current period results at prior period monthly average exchange rates.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including management's expectations regarding growth in orders, gross profit margins, revenues and adjusted EBITDA, ability to meet financial targets, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company's ability to convert backlog to revenue; the success of the adoption of our CyberKnife and TomoTherapy Systems; the company's ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, which was filed on August 28, 2015, the company's report on Form 10-Q, which was filed on November 5, 2015 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Financial Tables to Follow
Accuray Incorporated
Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
Three Months Ended December 31,
Six Months Ended December 31,
2015
2014
2015
2014
Gross Orders
$ 67,078
$ 72,261
$ 132,006
$ 131,024
Net Orders
42,679
41,474
87,478
73,756
Order Backlog
366,668
357,831
366,668
357,831
Net revenue:
Products
$ 55,759
$ 47,650
$ 95,754
$ 80,665
Services
53,153
50,505
102,789
99,871
Total net revenue
108,912
98,155
198,543
180,536
Cost of revenue:
Cost of products
32,717
27,171
55,734
47,836
Cost of services
33,624
32,495
66,340
66,410
Total cost of revenue
66,341
59,666
122,074
114,246
Gross profit
42,571
38,489
76,469
66,290
Operating expenses:
Research and development
14,931
13,917
29,227
28,066
Selling and marketing
15,076
15,802
28,493
33,776
General and administrative
12,688
12,361
26,104
23,311
Total operating expenses
42,695
42,080
83,824
85,153
Loss from operations
(124)
(3,591)
(7,355)
(18,863)
Other expense, net
(5,070)
(5,528)
(10,161)
(10,989)
Loss before provision for income taxes
(5,194)
(9,119)
(17,516)
(29,852)
Provision for income taxes
833
873
1,537
1,790
Net loss
$ (6,027)
$ (9,992)
$ (19,053)
$ (31,642)
Net loss per share - basic and diluted
$ (0.08)
$ (0.13)
$ (0.24)
$ (0.41)
Weighted average common shares used in computing loss per share:
Basic and diluted
80,346
77,924
80,053
77,607
Accuray Incorporated
Consolidated Balance Sheets
(in thousands)
(Unaudited)
December 31,
June 30,
2015
2015
Assets
Current assets:
Cash and cash equivalents
$ 88,451
$ 79,551
Investments
67,304
64,306
Restricted cash
2,596
3,734
Accounts receivable, net
66,044
77,727
Inventories
111,513
106,151
Prepaid expenses and other current assets
13,598
15,991
Deferred cost of revenue
8,834
6,869
Total current assets
358,340
354,329
Property and equipment, net
29,550
31,829
Goodwill
57,892
58,054
Intangible assets, net
11,587
15,564
Deferred cost of revenue
2,152
1,500
Other assets
13,804
8,695
Total assets
$ 473,325
$ 469,971
Liabilities and equity
Current liabilities:
Accounts payable
$ 19,561
$ 13,096
Accrued compensation
20,484
21,934
Other accrued liabilities
23,839
18,720
Short-term debt
96,551
-
Customer advances
19,377
19,385
Deferred revenue
94,386
96,780
Total current liabilities
274,198
169,915
Long-term liabilities:
Long-term other liabilities
10,829
10,934
Deferred revenue
17,257
10,489
Long-term debt
110,172
202,853
Total liabilities
412,456
394,191
Commitment and contingencies
Equity:
Common stock
81
79
Additional paid-in capital
476,387
471,430
Accumulated other comprehensive loss
(1,243)
(426)
Accumulated deficit
(414,356)
(395,303)
Total equity
60,869
75,780
Total liabilities and equity
$ 473,325
$ 469,971
Accuray Incorporated
Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes, Depreciation,
Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Three Months Ended December 31,
Six Months Ended December 31,
2015
2014
2015
2014
GAAP net loss
$ (6,027)
$ (9,992)
$ (19,053)
$ (31,642)
Amortization of intangibles (a)
1,988
1,988
3,976
3,976
Depreciation (b)
2,514
2,994
5,085
5,984
Stock-based compensation (c)
3,365
3,854
5,879
7,127
Interest expense, net (d)
4,138
4,023
8,294
8,011
Provision for income taxes
833
873
1,537
1,790
Adjusted EBITDA
$ 6,811
$ 3,740
$ 5,718
$ (4,754)
(a)
consists of amortization of intangibles - developed technology.
(b)
consists of depreciation, primarily on property and equipment.
(c)
consists of stock-based compensation in accordance with ASC 718.
(d)
consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes.
Accuray Incorporated
Forward-Looking Guidance
Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Twelve Months Ending June 30, 2016
From
To
GAAP net loss
$ (28,200)
$ (18,300)
Amortization of intangibles (a)
7,950
7,950
Depreciation (b)
10,850
10,850
Stock-based compensation (c)
14,100
14,100
Interest expense, net (d)
17,300
17,300
Provision for income taxes
3,000
3,100
Adjusted EBITDA
$ 25,000
$ 35,000
(a)
consists of amortization of intangibles - developed technology.
(b)
consists of depreciation, primarily on property and equipment.
(c)
consists of stock-based compensation in accordance with ASC 718.
(d)
consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes.
Logo - photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-generates-1089-million-in-second-quarter-revenues-300211580.html
SOURCE Accuray Incorporated
Source: PR Newswire (Jan 28, 2016 16:02:00 EST)
News by QuoteMedia
www.quotemedia.com
Accuray Generates $108.9 Million in Second Quarter Revenues
Record Revenues Achieved as Commercial Execution Continues; Management Reaffirms Fiscal 2016 Guidance
SUNNYVALE, Calif., Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015.
Fiscal Second Quarter Highlights
Gross orders were $67.1 million; single and dual vault sites comprised more than 50 percent of total TomoTherapy® System orders; replacement orders to existing accounts comprised approximately 15 percent of all system orders
Total revenue was $108.9 million, an increase of 11 percent year-over-year or 15 percent on a constant currency basis
Gross profit margins expanded sequentially to 39.1 percent from 37.8 percent
Operating income was near breakeven compared to a loss of $3.6 million in the prior year
Adjusted EBITDA was $6.8 million compared to $3.7 million in the prior year
Cash, cash equivalents and investments increased $2.7 million compared to a decrease of $1.9 million in the prior year
"In the second quarter we achieved an all time high revenue quarter and near breakeven operating income, demonstrating that we are continuing to execute on each of our strategic commercial initiatives. Based on our commercial momentum, we expect that order and revenue growth in the second half of the fiscal year will be at levels well above overall market growth," said Joshua H. Levine, president and chief executive officer of Accuray. "Additionally, in January 2016 we took steps to improve our capital structure by closing on a $70 million senior secured loan and subsequently retiring $63.4 million of convertible notes which were to mature in August 2016. We believe this demonstrates confidence on the part of the financial community in our ability to execute our commercial strategies and drive positive EBITDA. With the retirement of the notes and our intent to pay the remaining convertible notes in cash we have reduced potential dilution by 10.6 million shares of our common stock."
Financial Highlights
Gross product orders totaled $67.1 million for the second fiscal quarter. Ending product backlog was $366.7 million.
Total revenue was $108.9 million, an increase of 11 percent from the prior fiscal year second quarter and an increase of 15 percent on a constant currency basis. The Americas region total revenue was $51.0 million and total revenue outside of the Americas region was $57.9 million. Product revenue increased 17 percent to $55.8 million while service revenue increased 5 percent to $53.1 million.
Total gross profit was $42.6 million or 39 percent of sales, comprised of product gross margin of 41 percent and service gross margin of 37 percent. This compares to total gross margin of 39 percent, product gross margin of 43 percent and service gross margin of 36 percent for the prior fiscal year second quarter. On a constant currency basis, total gross margin for the second quarter of fiscal 2016 was 41 percent.
Operating expenses were $42.7 million, an increase of 1 percent compared with $42.1 million in the prior fiscal second quarter. The increase was primarily due to higher legal expenses, related to the amended award of $2.1 million for damages to the Company's former China distributor as well as increased research and development expenses to support ongoing product development efforts. These increases were partially offset by reduced compensation related expenses in sales and marketing and general and administrative functions.
In November 2015 Accuray's former distributor in China was awarded an interim award for damages of approximately $3.4 million. In January 2016, the International Chamber of Commerce International Court of Arbitration revised the award based on a clerical error they believe occurred in their calculation of the maximum amount of damages. Accuray incurred an additional $2.1 million in expenses related to this amended award in the second quarter of fiscal 2016. The remaining issue to be finalized in the arbitration relates to the payment of attorneys' fees.
Net loss improved to $6.0 million, or $0.08 per share, for the second quarter of fiscal 2016, compared to a net loss of $10.0 million, or $0.13 per share, for the second quarter of fiscal 2015.
Adjusted EBITDA for the second quarter of fiscal 2016 was $6.8 million, compared to $3.7 million in the second quarter of the prior fiscal year.
Cash, cash equivalents and investments were $155.8 million as of December 31, 2015, an increase of $2.7 million from September 30, 2015.
Six Month Highlights
For the six months ended December 31, 2015, total revenue reached $198.5 million, representing an increase of 10 percent or 14 percent on a constant currency basis, from the comparable period of fiscal year 2015. Product revenue for the six month period was $95.8 million, representing an increase of 19 percent while service revenue was $102.8 million, representing 3% growth over the comparable prior fiscal year period.
Gross profit margin for the six months ended December 31, 2015 was 39 percent, comprised of product gross margin of 42 percent and service gross margin of 35 percent. This compares to total gross margin of 37 percent for the comparable prior fiscal year period.
Operating expenses were $83.8 million for the six months ended December 31, 2015, compared with $85.2 million in the comparable prior fiscal year period.
Net loss for the six months ended December 31, 2015 was $19.1 million, or $0.24 per share, compared to a net loss of $31.6 million, or $0.41 per share, for the comparable prior fiscal year period.
Adjusted EBITDA for the six months ended December 31, 2015 was a positive $5.7 million, compared to a loss of $4.8 million in the comparable prior fiscal year period.
Cash, cash equivalents, and investments increased $11.9 million from June 30, 2015.
2016 Financial Guidance
Accuray reaffirmed previously provided financial guidance for fiscal 2016. Total revenue is expected to be between $395 million to $410 million and adjusted EBITDA is expected to range between $25 million to $35 million. Accuray continues to expect that gross orders for the fiscal year will be approximately $295 million, which would represent a 10 percent increase year over year.
This financial guidance is unchanged from that provided on January 11, 2016.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss these results. Conference call dial-in information is as follows:
U.S. callers: (855) 867-4103
International callers: (262) 912-4764
Conference ID Number (U.S. and international): 19257397
Individuals interested in listening to the live conference call via the Internet may do so by logging on to Accuray's website, In addition, a dial-up replay of the conference call will be available beginning January 28, 2016 at 5:00 p.m. PT/8:00 p.m. ET and ending February 4, 2016. The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International), Conference ID: 19257397.
Use of Non-GAAP Financial Measures
Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedule below.
Accuray presents certain measures, such as period-over-period revenue growth, on a constant currency basis, which excludes the effects of foreign currency translation. Due to the continuing strengthening of the U.S. dollar against foreign currencies and the overall variability of foreign exchange rates from period to period, management uses these measures on a constant currency basis to evaluate period-over-period operating performance. Measures presented on a constant currency basis are calculated by translating current period results at prior period monthly average exchange rates.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including management's expectations regarding growth in orders, gross profit margins, revenues and adjusted EBITDA, ability to meet financial targets, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company's ability to convert backlog to revenue; the success of the adoption of our CyberKnife and TomoTherapy Systems; the company's ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, which was filed on August 28, 2015, the company's report on Form 10-Q, which was filed on November 5, 2015 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Financial Tables to Follow
Accuray Incorporated
Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
Three Months Ended December 31,
Six Months Ended December 31,
2015
2014
2015
2014
Gross Orders
$ 67,078
$ 72,261
$ 132,006
$ 131,024
Net Orders
42,679
41,474
87,478
73,756
Order Backlog
366,668
357,831
366,668
357,831
Net revenue:
Products
$ 55,759
$ 47,650
$ 95,754
$ 80,665
Services
53,153
50,505
102,789
99,871
Total net revenue
108,912
98,155
198,543
180,536
Cost of revenue:
Cost of products
32,717
27,171
55,734
47,836
Cost of services
33,624
32,495
66,340
66,410
Total cost of revenue
66,341
59,666
122,074
114,246
Gross profit
42,571
38,489
76,469
66,290
Operating expenses:
Research and development
14,931
13,917
29,227
28,066
Selling and marketing
15,076
15,802
28,493
33,776
General and administrative
12,688
12,361
26,104
23,311
Total operating expenses
42,695
42,080
83,824
85,153
Loss from operations
(124)
(3,591)
(7,355)
(18,863)
Other expense, net
(5,070)
(5,528)
(10,161)
(10,989)
Loss before provision for income taxes
(5,194)
(9,119)
(17,516)
(29,852)
Provision for income taxes
833
873
1,537
1,790
Net loss
$ (6,027)
$ (9,992)
$ (19,053)
$ (31,642)
Net loss per share - basic and diluted
$ (0.08)
$ (0.13)
$ (0.24)
$ (0.41)
Weighted average common shares used in computing loss per share:
Basic and diluted
80,346
77,924
80,053
77,607
Accuray Incorporated
Consolidated Balance Sheets
(in thousands)
(Unaudited)
December 31,
June 30,
2015
2015
Assets
Current assets:
Cash and cash equivalents
$ 88,451
$ 79,551
Investments
67,304
64,306
Restricted cash
2,596
3,734
Accounts receivable, net
66,044
77,727
Inventories
111,513
106,151
Prepaid expenses and other current assets
13,598
15,991
Deferred cost of revenue
8,834
6,869
Total current assets
358,340
354,329
Property and equipment, net
29,550
31,829
Goodwill
57,892
58,054
Intangible assets, net
11,587
15,564
Deferred cost of revenue
2,152
1,500
Other assets
13,804
8,695
Total assets
$ 473,325
$ 469,971
Liabilities and equity
Current liabilities:
Accounts payable
$ 19,561
$ 13,096
Accrued compensation
20,484
21,934
Other accrued liabilities
23,839
18,720
Short-term debt
96,551
-
Customer advances
19,377
19,385
Deferred revenue
94,386
96,780
Total current liabilities
274,198
169,915
Long-term liabilities:
Long-term other liabilities
10,829
10,934
Deferred revenue
17,257
10,489
Long-term debt
110,172
202,853
Total liabilities
412,456
394,191
Commitment and contingencies
Equity:
Common stock
81
79
Additional paid-in capital
476,387
471,430
Accumulated other comprehensive loss
(1,243)
(426)
Accumulated deficit
(414,356)
(395,303)
Total equity
60,869
75,780
Total liabilities and equity
$ 473,325
$ 469,971
Accuray Incorporated
Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes, Depreciation,
Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Three Months Ended December 31,
Six Months Ended December 31,
2015
2014
2015
2014
GAAP net loss
$ (6,027)
$ (9,992)
$ (19,053)
$ (31,642)
Amortization of intangibles (a)
1,988
1,988
3,976
3,976
Depreciation (b)
2,514
2,994
5,085
5,984
Stock-based compensation (c)
3,365
3,854
5,879
7,127
Interest expense, net (d)
4,138
4,023
8,294
8,011
Provision for income taxes
833
873
1,537
1,790
Adjusted EBITDA
$ 6,811
$ 3,740
$ 5,718
$ (4,754)
(a)
consists of amortization of intangibles - developed technology.
(b)
consists of depreciation, primarily on property and equipment.
(c)
consists of stock-based compensation in accordance with ASC 718.
(d)
consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes.
Accuray Incorporated
Forward-Looking Guidance
Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Twelve Months Ending June 30, 2016
From
To
GAAP net loss
$ (28,200)
$ (18,300)
Amortization of intangibles (a)
7,950
7,950
Depreciation (b)
10,850
10,850
Stock-based compensation (c)
14,100
14,100
Interest expense, net (d)
17,300
17,300
Provision for income taxes
3,000
3,100
Adjusted EBITDA
$ 25,000
$ 35,000
(a)
consists of amortization of intangibles - developed technology.
(b)
consists of depreciation, primarily on property and equipment.
(c)
consists of stock-based compensation in accordance with ASC 718.
(d)
consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes.
Logo - photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-generates-1089-million-in-second-quarter-revenues-300211580.html
SOURCE Accuray Incorporated
Source: PR Newswire (Jan 28, 2016 16:02:00 EST)
News by QuoteMedia
www.quotemedia.com
SUNNYVALE, Calif., Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015.
Fiscal Second Quarter Highlights
Gross orders were $67.1 million; single and dual vault sites comprised more than 50 percent of total TomoTherapy® System orders; replacement orders to existing accounts comprised approximately 15 percent of all system orders
Total revenue was $108.9 million, an increase of 11 percent year-over-year or 15 percent on a constant currency basis
Gross profit margins expanded sequentially to 39.1 percent from 37.8 percent
Operating income was near breakeven compared to a loss of $3.6 million in the prior year
Adjusted EBITDA was $6.8 million compared to $3.7 million in the prior year
Cash, cash equivalents and investments increased $2.7 million compared to a decrease of $1.9 million in the prior year
"In the second quarter we achieved an all time high revenue quarter and near breakeven operating income, demonstrating that we are continuing to execute on each of our strategic commercial initiatives. Based on our commercial momentum, we expect that order and revenue growth in the second half of the fiscal year will be at levels well above overall market growth," said Joshua H. Levine, president and chief executive officer of Accuray. "Additionally, in January 2016 we took steps to improve our capital structure by closing on a $70 million senior secured loan and subsequently retiring $63.4 million of convertible notes which were to mature in August 2016. We believe this demonstrates confidence on the part of the financial community in our ability to execute our commercial strategies and drive positive EBITDA. With the retirement of the notes and our intent to pay the remaining convertible notes in cash we have reduced potential dilution by 10.6 million shares of our common stock."
Financial Highlights
Gross product orders totaled $67.1 million for the second fiscal quarter. Ending product backlog was $366.7 million.
Total revenue was $108.9 million, an increase of 11 percent from the prior fiscal year second quarter and an increase of 15 percent on a constant currency basis. The Americas region total revenue was $51.0 million and total revenue outside of the Americas region was $57.9 million. Product revenue increased 17 percent to $55.8 million while service revenue increased 5 percent to $53.1 million.
Total gross profit was $42.6 million or 39 percent of sales, comprised of product gross margin of 41 percent and service gross margin of 37 percent. This compares to total gross margin of 39 percent, product gross margin of 43 percent and service gross margin of 36 percent for the prior fiscal year second quarter. On a constant currency basis, total gross margin for the second quarter of fiscal 2016 was 41 percent.
Operating expenses were $42.7 million, an increase of 1 percent compared with $42.1 million in the prior fiscal second quarter. The increase was primarily due to higher legal expenses, related to the amended award of $2.1 million for damages to the Company's former China distributor as well as increased research and development expenses to support ongoing product development efforts. These increases were partially offset by reduced compensation related expenses in sales and marketing and general and administrative functions.
In November 2015 Accuray's former distributor in China was awarded an interim award for damages of approximately $3.4 million. In January 2016, the International Chamber of Commerce International Court of Arbitration revised the award based on a clerical error they believe occurred in their calculation of the maximum amount of damages. Accuray incurred an additional $2.1 million in expenses related to this amended award in the second quarter of fiscal 2016. The remaining issue to be finalized in the arbitration relates to the payment of attorneys' fees.
Net loss improved to $6.0 million, or $0.08 per share, for the second quarter of fiscal 2016, compared to a net loss of $10.0 million, or $0.13 per share, for the second quarter of fiscal 2015.
Adjusted EBITDA for the second quarter of fiscal 2016 was $6.8 million, compared to $3.7 million in the second quarter of the prior fiscal year.
Cash, cash equivalents and investments were $155.8 million as of December 31, 2015, an increase of $2.7 million from September 30, 2015.
Six Month Highlights
For the six months ended December 31, 2015, total revenue reached $198.5 million, representing an increase of 10 percent or 14 percent on a constant currency basis, from the comparable period of fiscal year 2015. Product revenue for the six month period was $95.8 million, representing an increase of 19 percent while service revenue was $102.8 million, representing 3% growth over the comparable prior fiscal year period.
Gross profit margin for the six months ended December 31, 2015 was 39 percent, comprised of product gross margin of 42 percent and service gross margin of 35 percent. This compares to total gross margin of 37 percent for the comparable prior fiscal year period.
Operating expenses were $83.8 million for the six months ended December 31, 2015, compared with $85.2 million in the comparable prior fiscal year period.
Net loss for the six months ended December 31, 2015 was $19.1 million, or $0.24 per share, compared to a net loss of $31.6 million, or $0.41 per share, for the comparable prior fiscal year period.
Adjusted EBITDA for the six months ended December 31, 2015 was a positive $5.7 million, compared to a loss of $4.8 million in the comparable prior fiscal year period.
Cash, cash equivalents, and investments increased $11.9 million from June 30, 2015.
2016 Financial Guidance
Accuray reaffirmed previously provided financial guidance for fiscal 2016. Total revenue is expected to be between $395 million to $410 million and adjusted EBITDA is expected to range between $25 million to $35 million. Accuray continues to expect that gross orders for the fiscal year will be approximately $295 million, which would represent a 10 percent increase year over year.
This financial guidance is unchanged from that provided on January 11, 2016.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss these results. Conference call dial-in information is as follows:
U.S. callers: (855) 867-4103
International callers: (262) 912-4764
Conference ID Number (U.S. and international): 19257397
Accuray Generates $108.9 Million in Second Quarter Revenues
Record Revenues Achieved as Commercial Execution Continues; Management Reaffirms Fiscal 2016 Guidance
SUNNYVALE, Calif., Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015.
Fiscal Second Quarter Highlights
Gross orders were $67.1 million; single and dual vault sites comprised more than 50 percent of total TomoTherapy® System orders; replacement orders to existing accounts comprised approximately 15 percent of all system orders
Total revenue was $108.9 million, an increase of 11 percent year-over-year or 15 percent on a constant currency basis
Gross profit margins expanded sequentially to 39.1 percent from 37.8 percent
Operating income was near breakeven compared to a loss of $3.6 million in the prior year
Adjusted EBITDA was $6.8 million compared to $3.7 million in the prior year
Cash, cash equivalents and investments increased $2.7 million compared to a decrease of $1.9 million in the prior year
"In the second quarter we achieved an all time high revenue quarter and near breakeven operating income, demonstrating that we are continuing to execute on each of our strategic commercial initiatives. Based on our commercial momentum, we expect that order and revenue growth in the second half of the fiscal year will be at levels well above overall market growth," said Joshua H. Levine, president and chief executive officer of Accuray. "Additionally, in January 2016 we took steps to improve our capital structure by closing on a $70 million senior secured loan and subsequently retiring $63.4 million of convertible notes which were to mature in August 2016. We believe this demonstrates confidence on the part of the financial community in our ability to execute our commercial strategies and drive positive EBITDA. With the retirement of the notes and our intent to pay the remaining convertible notes in cash we have reduced potential dilution by 10.6 million shares of our common stock."
Financial Highlights
Gross product orders totaled $67.1 million for the second fiscal quarter. Ending product backlog was $366.7 million.
Total revenue was $108.9 million, an increase of 11 percent from the prior fiscal year second quarter and an increase of 15 percent on a constant currency basis. The Americas region total revenue was $51.0 million and total revenue outside of the Americas region was $57.9 million. Product revenue increased 17 percent to $55.8 million while service revenue increased 5 percent to $53.1 million.
Total gross profit was $42.6 million or 39 percent of sales, comprised of product gross margin of 41 percent and service gross margin of 37 percent. This compares to total gross margin of 39 percent, product gross margin of 43 percent and service gross margin of 36 percent for the prior fiscal year second quarter. On a constant currency basis, total gross margin for the second quarter of fiscal 2016 was 41 percent.
Operating expenses were $42.7 million, an increase of 1 percent compared with $42.1 million in the prior fiscal second quarter. The increase was primarily due to higher legal expenses, related to the amended award of $2.1 million for damages to the Company's former China distributor as well as increased research and development expenses to support ongoing product development efforts. These increases were partially offset by reduced compensation related expenses in sales and marketing and general and administrative functions.
In November 2015 Accuray's former distributor in China was awarded an interim award for damages of approximately $3.4 million. In January 2016, the International Chamber of Commerce International Court of Arbitration revised the award based on a clerical error they believe occurred in their calculation of the maximum amount of damages. Accuray incurred an additional $2.1 million in expenses related to this amended award in the second quarter of fiscal 2016. The remaining issue to be finalized in the arbitration relates to the payment of attorneys' fees.
Net loss improved to $6.0 million, or $0.08 per share, for the second quarter of fiscal 2016, compared to a net loss of $10.0 million, or $0.13 per share, for the second quarter of fiscal 2015.
Adjusted EBITDA for the second quarter of fiscal 2016 was $6.8 million, compared to $3.7 million in the second quarter of the prior fiscal year.
Cash, cash equivalents and investments were $155.8 million as of December 31, 2015, an increase of $2.7 million from September 30, 2015.
Six Month Highlights
For the six months ended December 31, 2015, total revenue reached $198.5 million, representing an increase of 10 percent or 14 percent on a constant currency basis, from the comparable period of fiscal year 2015. Product revenue for the six month period was $95.8 million, representing an increase of 19 percent while service revenue was $102.8 million, representing 3% growth over the comparable prior fiscal year period.
Gross profit margin for the six months ended December 31, 2015 was 39 percent, comprised of product gross margin of 42 percent and service gross margin of 35 percent. This compares to total gross margin of 37 percent for the comparable prior fiscal year period.
Operating expenses were $83.8 million for the six months ended December 31, 2015, compared with $85.2 million in the comparable prior fiscal year period.
Net loss for the six months ended December 31, 2015 was $19.1 million, or $0.24 per share, compared to a net loss of $31.6 million, or $0.41 per share, for the comparable prior fiscal year period.
Adjusted EBITDA for the six months ended December 31, 2015 was a positive $5.7 million, compared to a loss of $4.8 million in the comparable prior fiscal year period.
Cash, cash equivalents, and investments increased $11.9 million from June 30, 2015.
2016 Financial Guidance
Accuray reaffirmed previously provided financial guidance for fiscal 2016. Total revenue is expected to be between $395 million to $410 million and adjusted EBITDA is expected to range between $25 million to $35 million. Accuray continues to expect that gross orders for the fiscal year will be approximately $295 million, which would represent a 10 percent increase year over year.
This financial guidance is unchanged from that provided on January 11, 2016.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss these results. Conference call dial-in information is as follows:
U.S. callers: (855) 867-4103
International callers: (262) 912-4764
Conference ID Number (U.S. and international): 19257397
Individuals interested in listening to the live conference call via the Internet may do so by logging on to Accuray's website, In addition, a dial-up replay of the conference call will be available beginning January 28, 2016 at 5:00 p.m. PT/8:00 p.m. ET and ending February 4, 2016. The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International), Conference ID: 19257397.
Use of Non-GAAP Financial Measures
Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedule below.
Accuray presents certain measures, such as period-over-period revenue growth, on a constant currency basis, which excludes the effects of foreign currency translation. Due to the continuing strengthening of the U.S. dollar against foreign currencies and the overall variability of foreign exchange rates from period to period, management uses these measures on a constant currency basis to evaluate period-over-period operating performance. Measures presented on a constant currency basis are calculated by translating current period results at prior period monthly average exchange rates.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including management's expectations regarding growth in orders, gross profit margins, revenues and adjusted EBITDA, ability to meet financial targets, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company's ability to convert backlog to revenue; the success of the adoption of our CyberKnife and TomoTherapy Systems; the company's ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, which was filed on August 28, 2015, the company's report on Form 10-Q, which was filed on November 5, 2015 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Financial Tables to Follow
Accuray Incorporated
Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
Three Months Ended December 31,
Six Months Ended December 31,
2015
2014
2015
2014
Gross Orders
$ 67,078
$ 72,261
$ 132,006
$ 131,024
Net Orders
42,679
41,474
87,478
73,756
Order Backlog
366,668
357,831
366,668
357,831
Net revenue:
Products
$ 55,759
$ 47,650
$ 95,754
$ 80,665
Services
53,153
50,505
102,789
99,871
Total net revenue
108,912
98,155
198,543
180,536
Cost of revenue:
Cost of products
32,717
27,171
55,734
47,836
Cost of services
33,624
32,495
66,340
66,410
Total cost of revenue
66,341
59,666
122,074
114,246
Gross profit
42,571
38,489
76,469
66,290
Operating expenses:
Research and development
14,931
13,917
29,227
28,066
Selling and marketing
15,076
15,802
28,493
33,776
General and administrative
12,688
12,361
26,104
23,311
Total operating expenses
42,695
42,080
83,824
85,153
Loss from operations
(124)
(3,591)
(7,355)
(18,863)
Other expense, net
(5,070)
(5,528)
(10,161)
(10,989)
Loss before provision for income taxes
(5,194)
(9,119)
(17,516)
(29,852)
Provision for income taxes
833
873
1,537
1,790
Net loss
$ (6,027)
$ (9,992)
$ (19,053)
$ (31,642)
Net loss per share - basic and diluted
$ (0.08)
$ (0.13)
$ (0.24)
$ (0.41)
Weighted average common shares used in computing loss per share:
Basic and diluted
80,346
77,924
80,053
77,607
Accuray Incorporated
Consolidated Balance Sheets
(in thousands)
(Unaudited)
December 31,
June 30,
2015
2015
Assets
Current assets:
Cash and cash equivalents
$ 88,451
$ 79,551
Investments
67,304
64,306
Restricted cash
2,596
3,734
Accounts receivable, net
66,044
77,727
Inventories
111,513
106,151
Prepaid expenses and other current assets
13,598
15,991
Deferred cost of revenue
8,834
6,869
Total current assets
358,340
354,329
Property and equipment, net
29,550
31,829
Goodwill
57,892
58,054
Intangible assets, net
11,587
15,564
Deferred cost of revenue
2,152
1,500
Other assets
13,804
8,695
Total assets
$ 473,325
$ 469,971
Liabilities and equity
Current liabilities:
Accounts payable
$ 19,561
$ 13,096
Accrued compensation
20,484
21,934
Other accrued liabilities
23,839
18,720
Short-term debt
96,551
-
Customer advances
19,377
19,385
Deferred revenue
94,386
96,780
Total current liabilities
274,198
169,915
Long-term liabilities:
Long-term other liabilities
10,829
10,934
Deferred revenue
17,257
10,489
Long-term debt
110,172
202,853
Total liabilities
412,456
394,191
Commitment and contingencies
Equity:
Common stock
81
79
Additional paid-in capital
476,387
471,430
Accumulated other comprehensive loss
(1,243)
(426)
Accumulated deficit
(414,356)
(395,303)
Total equity
60,869
75,780
Total liabilities and equity
$ 473,325
$ 469,971
Accuray Incorporated
Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes, Depreciation,
Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Three Months Ended December 31,
Six Months Ended December 31,
2015
2014
2015
2014
GAAP net loss
$ (6,027)
$ (9,992)
$ (19,053)
$ (31,642)
Amortization of intangibles (a)
1,988
1,988
3,976
3,976
Depreciation (b)
2,514
2,994
5,085
5,984
Stock-based compensation (c)
3,365
3,854
5,879
7,127
Interest expense, net (d)
4,138
4,023
8,294
8,011
Provision for income taxes
833
873
1,537
1,790
Adjusted EBITDA
$ 6,811
$ 3,740
$ 5,718
$ (4,754)
(a)
consists of amortization of intangibles - developed technology.
(b)
consists of depreciation, primarily on property and equipment.
(c)
consists of stock-based compensation in accordance with ASC 718.
(d)
consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes.
Accuray Incorporated
Forward-Looking Guidance
Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Twelve Months Ending June 30, 2016
From
To
GAAP net loss
$ (28,200)
$ (18,300)
Amortization of intangibles (a)
7,950
7,950
Depreciation (b)
10,850
10,850
Stock-based compensation (c)
14,100
14,100
Interest expense, net (d)
17,300
17,300
Provision for income taxes
3,000
3,100
Adjusted EBITDA
$ 25,000
$ 35,000
(a)
consists of amortization of intangibles - developed technology.
(b)
consists of depreciation, primarily on property and equipment.
(c)
consists of stock-based compensation in accordance with ASC 718.
(d)
consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes.
Logo - photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-generates-1089-million-in-second-quarter-revenues-300211580.html
SOURCE Accuray Incorporated
Source: PR Newswire (Jan 28, 2016 16:02:00 EST)
News by QuoteMedia
www.quotemedia.com
Accuray Generates $108.9 Million in Second Quarter Revenues
Record Revenues Achieved as Commercial Execution Continues; Management Reaffirms Fiscal 2016 Guidance
SUNNYVALE, Calif., Jan. 28, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2015.
Fiscal Second Quarter Highlights
Gross orders were $67.1 million; single and dual vault sites comprised more than 50 percent of total TomoTherapy® System orders; replacement orders to existing accounts comprised approximately 15 percent of all system orders
Total revenue was $108.9 million, an increase of 11 percent year-over-year or 15 percent on a constant currency basis
Gross profit margins expanded sequentially to 39.1 percent from 37.8 percent
Operating income was near breakeven compared to a loss of $3.6 million in the prior year
Adjusted EBITDA was $6.8 million compared to $3.7 million in the prior year
Cash, cash equivalents and investments increased $2.7 million compared to a decrease of $1.9 million in the prior year
"In the second quarter we achieved an all time high revenue quarter and near breakeven operating income, demonstrating that we are continuing to execute on each of our strategic commercial initiatives. Based on our commercial momentum, we expect that order and revenue growth in the second half of the fiscal year will be at levels well above overall market growth," said Joshua H. Levine, president and chief executive officer of Accuray. "Additionally, in January 2016 we took steps to improve our capital structure by closing on a $70 million senior secured loan and subsequently retiring $63.4 million of convertible notes which were to mature in August 2016. We believe this demonstrates confidence on the part of the financial community in our ability to execute our commercial strategies and drive positive EBITDA. With the retirement of the notes and our intent to pay the remaining convertible notes in cash we have reduced potential dilution by 10.6 million shares of our common stock."
Financial Highlights
Gross product orders totaled $67.1 million for the second fiscal quarter. Ending product backlog was $366.7 million.
Total revenue was $108.9 million, an increase of 11 percent from the prior fiscal year second quarter and an increase of 15 percent on a constant currency basis. The Americas region total revenue was $51.0 million and total revenue outside of the Americas region was $57.9 million. Product revenue increased 17 percent to $55.8 million while service revenue increased 5 percent to $53.1 million.
Total gross profit was $42.6 million or 39 percent of sales, comprised of product gross margin of 41 percent and service gross margin of 37 percent. This compares to total gross margin of 39 percent, product gross margin of 43 percent and service gross margin of 36 percent for the prior fiscal year second quarter. On a constant currency basis, total gross margin for the second quarter of fiscal 2016 was 41 percent.
Operating expenses were $42.7 million, an increase of 1 percent compared with $42.1 million in the prior fiscal second quarter. The increase was primarily due to higher legal expenses, related to the amended award of $2.1 million for damages to the Company's former China distributor as well as increased research and development expenses to support ongoing product development efforts. These increases were partially offset by reduced compensation related expenses in sales and marketing and general and administrative functions.
In November 2015 Accuray's former distributor in China was awarded an interim award for damages of approximately $3.4 million. In January 2016, the International Chamber of Commerce International Court of Arbitration revised the award based on a clerical error they believe occurred in their calculation of the maximum amount of damages. Accuray incurred an additional $2.1 million in expenses related to this amended award in the second quarter of fiscal 2016. The remaining issue to be finalized in the arbitration relates to the payment of attorneys' fees.
Net loss improved to $6.0 million, or $0.08 per share, for the second quarter of fiscal 2016, compared to a net loss of $10.0 million, or $0.13 per share, for the second quarter of fiscal 2015.
Adjusted EBITDA for the second quarter of fiscal 2016 was $6.8 million, compared to $3.7 million in the second quarter of the prior fiscal year.
Cash, cash equivalents and investments were $155.8 million as of December 31, 2015, an increase of $2.7 million from September 30, 2015.
Six Month Highlights
For the six months ended December 31, 2015, total revenue reached $198.5 million, representing an increase of 10 percent or 14 percent on a constant currency basis, from the comparable period of fiscal year 2015. Product revenue for the six month period was $95.8 million, representing an increase of 19 percent while service revenue was $102.8 million, representing 3% growth over the comparable prior fiscal year period.
Gross profit margin for the six months ended December 31, 2015 was 39 percent, comprised of product gross margin of 42 percent and service gross margin of 35 percent. This compares to total gross margin of 37 percent for the comparable prior fiscal year period.
Operating expenses were $83.8 million for the six months ended December 31, 2015, compared with $85.2 million in the comparable prior fiscal year period.
Net loss for the six months ended December 31, 2015 was $19.1 million, or $0.24 per share, compared to a net loss of $31.6 million, or $0.41 per share, for the comparable prior fiscal year period.
Adjusted EBITDA for the six months ended December 31, 2015 was a positive $5.7 million, compared to a loss of $4.8 million in the comparable prior fiscal year period.
Cash, cash equivalents, and investments increased $11.9 million from June 30, 2015.
2016 Financial Guidance
Accuray reaffirmed previously provided financial guidance for fiscal 2016. Total revenue is expected to be between $395 million to $410 million and adjusted EBITDA is expected to range between $25 million to $35 million. Accuray continues to expect that gross orders for the fiscal year will be approximately $295 million, which would represent a 10 percent increase year over year.
This financial guidance is unchanged from that provided on January 11, 2016.
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss these results. Conference call dial-in information is as follows:
U.S. callers: (855) 867-4103
International callers: (262) 912-4764
Conference ID Number (U.S. and international): 19257397
Individuals interested in listening to the live conference call via the Internet may do so by logging on to Accuray's website, In addition, a dial-up replay of the conference call will be available beginning January 28, 2016 at 5:00 p.m. PT/8:00 p.m. ET and ending February 4, 2016. The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International), Conference ID: 19257397.
Use of Non-GAAP Financial Measures
Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedule below.
Accuray presents certain measures, such as period-over-period revenue growth, on a constant currency basis, which excludes the effects of foreign currency translation. Due to the continuing strengthening of the U.S. dollar against foreign currencies and the overall variability of foreign exchange rates from period to period, management uses these measures on a constant currency basis to evaluate period-over-period operating performance. Measures presented on a constant currency basis are calculated by translating current period results at prior period monthly average exchange rates.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including management's expectations regarding growth in orders, gross profit margins, revenues and adjusted EBITDA, ability to meet financial targets, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company's ability to convert backlog to revenue; the success of the adoption of our CyberKnife and TomoTherapy Systems; the company's ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, which was filed on August 28, 2015, the company's report on Form 10-Q, which was filed on November 5, 2015 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Financial Tables to Follow
Accuray Incorporated
Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
Three Months Ended December 31,
Six Months Ended December 31,
2015
2014
2015
2014
Gross Orders
$ 67,078
$ 72,261
$ 132,006
$ 131,024
Net Orders
42,679
41,474
87,478
73,756
Order Backlog
366,668
357,831
366,668
357,831
Net revenue:
Products
$ 55,759
$ 47,650
$ 95,754
$ 80,665
Services
53,153
50,505
102,789
99,871
Total net revenue
108,912
98,155
198,543
180,536
Cost of revenue:
Cost of products
32,717
27,171
55,734
47,836
Cost of services
33,624
32,495
66,340
66,410
Total cost of revenue
66,341
59,666
122,074
114,246
Gross profit
42,571
38,489
76,469
66,290
Operating expenses:
Research and development
14,931
13,917
29,227
28,066
Selling and marketing
15,076
15,802
28,493
33,776
General and administrative
12,688
12,361
26,104
23,311
Total operating expenses
42,695
42,080
83,824
85,153
Loss from operations
(124)
(3,591)
(7,355)
(18,863)
Other expense, net
(5,070)
(5,528)
(10,161)
(10,989)
Loss before provision for income taxes
(5,194)
(9,119)
(17,516)
(29,852)
Provision for income taxes
833
873
1,537
1,790
Net loss
$ (6,027)
$ (9,992)
$ (19,053)
$ (31,642)
Net loss per share - basic and diluted
$ (0.08)
$ (0.13)
$ (0.24)
$ (0.41)
Weighted average common shares used in computing loss per share:
Basic and diluted
80,346
77,924
80,053
77,607
Accuray Incorporated
Consolidated Balance Sheets
(in thousands)
(Unaudited)
December 31,
June 30,
2015
2015
Assets
Current assets:
Cash and cash equivalents
$ 88,451
$ 79,551
Investments
67,304
64,306
Restricted cash
2,596
3,734
Accounts receivable, net
66,044
77,727
Inventories
111,513
106,151
Prepaid expenses and other current assets
13,598
15,991
Deferred cost of revenue
8,834
6,869
Total current assets
358,340
354,329
Property and equipment, net
29,550
31,829
Goodwill
57,892
58,054
Intangible assets, net
11,587
15,564
Deferred cost of revenue
2,152
1,500
Other assets
13,804
8,695
Total assets
$ 473,325
$ 469,971
Liabilities and equity
Current liabilities:
Accounts payable
$ 19,561
$ 13,096
Accrued compensation
20,484
21,934
Other accrued liabilities
23,839
18,720
Short-term debt
96,551
-
Customer advances
19,377
19,385
Deferred revenue
94,386
96,780
Total current liabilities
274,198
169,915
Long-term liabilities:
Long-term other liabilities
10,829
10,934
Deferred revenue
17,257
10,489
Long-term debt
110,172
202,853
Total liabilities
412,456
394,191
Commitment and contingencies
Equity:
Common stock
81
79
Additional paid-in capital
476,387
471,430
Accumulated other comprehensive loss
(1,243)
(426)
Accumulated deficit
(414,356)
(395,303)
Total equity
60,869
75,780
Total liabilities and equity
$ 473,325
$ 469,971
Accuray Incorporated
Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes, Depreciation,
Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Three Months Ended December 31,
Six Months Ended December 31,
2015
2014
2015
2014
GAAP net loss
$ (6,027)
$ (9,992)
$ (19,053)
$ (31,642)
Amortization of intangibles (a)
1,988
1,988
3,976
3,976
Depreciation (b)
2,514
2,994
5,085
5,984
Stock-based compensation (c)
3,365
3,854
5,879
7,127
Interest expense, net (d)
4,138
4,023
8,294
8,011
Provision for income taxes
833
873
1,537
1,790
Adjusted EBITDA
$ 6,811
$ 3,740
$ 5,718
$ (4,754)
(a)
consists of amortization of intangibles - developed technology.
(b)
consists of depreciation, primarily on property and equipment.
(c)
consists of stock-based compensation in accordance with ASC 718.
(d)
consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes.
Accuray Incorporated
Forward-Looking Guidance
Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)
(in thousands)
(Unaudited)
Twelve Months Ending June 30, 2016
From
To
GAAP net loss
$ (28,200)
$ (18,300)
Amortization of intangibles (a)
7,950
7,950
Depreciation (b)
10,850
10,850
Stock-based compensation (c)
14,100
14,100
Interest expense, net (d)
17,300
17,300
Provision for income taxes
3,000
3,100
Adjusted EBITDA
$ 25,000
$ 35,000
(a)
consists of amortization of intangibles - developed technology.
(b)
consists of depreciation, primarily on property and equipment.
(c)
consists of stock-based compensation in accordance with ASC 718.
(d)
consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes.
Logo - photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-generates-1089-million-in-second-quarter-revenues-300211580.html
SOURCE Accuray Incorporated
Source: PR Newswire (Jan 28, 2016 16:02:00 EST)
News by QuoteMedia
www.quotemedia.com